Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23136615 | 0.80 | CDK2 (0.39) | MAPTGRM4MEN1KMT2AGRIA1 | |
| SCHEMBL25829484 | 0.77 | MAPT (0.43) | MAPTCYP19A1NQO2MAPK1L3MBTL1 | |
| SCHEMBL24459896 | 0.73 | KRAS (0.40) | CHEK1WEE1KRASEGFR | |
| SCHEMBL30534031 | 0.73 | KRAS (0.40) | CHEK1WEE1KRASEGFR | |
| SCHEMBL20373555 | 0.72 | F2RL3 (0.39) | KRASEGFRLMNA | |
| SCHEMBL18128619 | 0.70 | KRAS (0.44) | MAPTCYP3A4CYP2C19KRASMEN1 | |
| SCHEMBL18128526 | 0.70 | NQO2 (0.36) | MAPTNQO2CYP3A4CYP2C19KRAS | |
| SCHEMBL30253523 | 0.70 | GRIA1 (0.44) | NQO2CYP1A2CHEK1WEE1MEN1 | |
| SCHEMBL18395037 | 0.69 | PARP1 (0.47) | KRASGRIA1CACNG8EGFRPIM1 | |
| SCHEMBL2267619 | 0.68 | MAPT (0.53) | MAPTCYP19A1NQO2CYP1A2CTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| WO-2021052499-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | MAPT 4157/4885CYP19A1 737/4885NQO2 1381/4885 |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | MAPT 4157/4885CYP19A1 737/4885NQO2 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.